"Our data show the potential of SS-31 as a novel therapeutic in cardiac arrest"
"Previous studies tested SS-31 using different dosages invarious diseases [
3] and 0.05mg/kg/h is a commonly used dosage for continuous administration with consistent effectiveness"
"Mitochondrial dysfunction is believed to play an important role for the pathogenesis of cardiac arrest."
"The wide spectrum of protective action makes SS-31 a promising therapeutic agent in CA [cardiac arrest], where multiple organs are affected."